BioPharma Resources

Drug Trial Radar · NCT07318883

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

A Randomized, Double-Blind, Multicenter, Phase II/III Clinical Study to Evaluate HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody Injection) in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Patients With Advanced Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 720 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

720

Planned (sponsor's estimate)

Start

Mar 2026

Primary completion

Jan 2031

Study completion Jan 2031

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Jan 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study consists of two parts: Part I is a randomized, double-blind, multicenter, parallel-controlled phase II clinical study to evaluate the efficacy and safety of HLX07 in combination with serplulimab and chemotherapy versus placebo in combination with serplulimab and chemotherapy as first-line treatment in patients with sqNSCLC. Part II is a randomized, double-blind, multicenter, parallel-controlled phase III clinical study to evaluate the efficacy and safety of HLX07 in combination with serplulimab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy as first-line treatment in patients with sqNSCLC.

Conditions

  • Squamous NSCLC

Interventions

  • HLX07Drug

    Intravenous infusion (IV), once every 3 weeks (Day 1 of each cycle \[D1\]).

  • HLX07 placeboDrug

    Intravenous infusion (IV), once every 3 weeks (Day 1 of each cycle \[D1\]).

  • SerplulimabDrug

    IV, once every 3 weeks (D1).

  • PembrolizumabDrug

    IV, once every 3 weeks (D1).

  • CarboplatinDrug

    IV, once every 3 weeks (D1).

  • Paclitaxel or Nab-PaclitaxelDrug

    Paclitaxel: IV, once every 3 weeks (D1). Nab-paclitaxel: IV, once every 3 weeks (D1, 8, 15).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR assessed by BICR (part I)Time frame: Assessed up to appoximately 6 months from enrollment
  2. PFS assessed by BICR (part I)Time frame: Assessed up to appoximately 16 months from enrollment
  3. PFS assessed by BICR (part II)Time frame: Assessed up to appoximately 23 months from enrollment
  4. OS (part II)Time frame: Assessed up to appoximately 42 months from enrollment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.